FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3170396775> ?p ?o ?g. }

• W3170396775 endingPage "e13565" @default.
• W3170396775 startingPage "e13565" @default.
• W3170396775 abstract "e13565 Background: Data from traditional registries are usually limited to patients treated at study sites. Virtual registries can enroll a broader real-world population. Neat-HER is a U.S.-based virtual registry pilot through PicnicHealth that is enrolling patients with HER2+ breast cancer receiving neratinib as extended adjuvant therapy. Methods: Neat-HER evaluates the feasibility of enrolling patients and answering research questions using a novel electronic platform. Eligibility includes receipt of neratinib in the extended adjuvant setting, signed informed consent for medical record retrieval/data abstraction and age > 18 years. Patients who do not complete enrollment procedures, are participating in a clinical trial or have metastatic disease are excluded. Patients are recruited through multiple mechanisms including private social media groups, treating clinicians and patients enrolled in the Puma Texting Program. Patient health records for breast cancer-related treatment are collected from time of diagnosis to 1-year post-enrollment in the registry. Research questions focus on patient and tumor characteristics, receipt of therapy (e.g. radiotherapy, adjuvant therapy), neratinib duration, and diarrhea prophylaxis. Results: 33 patients with HER2+ early-stage breast cancer who received neratinib as extended adjuvant therapy have been enrolled in this registry study since December 2018. Median age was 50 years, with 79% of patients self-identifying as white. 82% of patients had hormone receptor-positive (ER/PR) disease and 73% of patients had node-positive disease. Prior HER2-targeted adjuvant therapy regimens were as follows: trastuzumab with paclitaxel (9%); trastuzumab/pertuzumab in combination with a taxane(s) (91%). 17 patients (52%) completed 12 months of neratinib treatment; 4 patients (12%) discontinued treatment early; 10 patients (30%) were still ongoing at the time of data cutoff. 31 patients (94%) had diarrhea prophylaxis discussed prior to the start of neratinib treatment. Conclusions: Neat-HER provides useful information on patient/tumor characteristics and treatment patterns in a real-world cohort receiving extended adjuvant neratinib and patient recruitment is ongoing. Updated results show that this pilot virtual registry continues to be a feasible and efficient modality to collect important data on descriptive characteristics and treatment patterns for a patient population derived from real-world practice settings. Validation of this method is needed and could be used in other tumor types." @default.
• W3170396775 created "2021-06-22" @default.
• W3170396775 creator A5023674071 @default.
• W3170396775 creator A5024882579 @default.
• W3170396775 creator A5043139740 @default.
• W3170396775 creator A5057389610 @default.
• W3170396775 creator A5063718631 @default.
• W3170396775 creator A5072015843 @default.
• W3170396775 creator A5073189857 @default.
• W3170396775 creator A5090188675 @default.
• W3170396775 date "2021-05-20" @default.
• W3170396775 modified "2023-09-27" @default.
• W3170396775 title "The Neat-HER virtual registry: Updated results on HER2+ breast cancer patients receiving neratinib as extended adjuvant therapy." @default.
• W3170396775 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e13565" @default.
• W3170396775 hasPublicationYear "2021" @default.
• W3170396775 type Work @default.
• W3170396775 sameAs 3170396775 @default.
• W3170396775 citedByCount "0" @default.
• W3170396775 crossrefType "journal-article" @default.
• W3170396775 hasAuthorship W3170396775A5023674071 @default.
• W3170396775 hasAuthorship W3170396775A5024882579 @default.
• W3170396775 hasAuthorship W3170396775A5043139740 @default.
• W3170396775 hasAuthorship W3170396775A5057389610 @default.
• W3170396775 hasAuthorship W3170396775A5063718631 @default.
• W3170396775 hasAuthorship W3170396775A5072015843 @default.
• W3170396775 hasAuthorship W3170396775A5073189857 @default.
• W3170396775 hasAuthorship W3170396775A5090188675 @default.
• W3170396775 hasConcept C121608353 @default.
• W3170396775 hasConcept C126322002 @default.
• W3170396775 hasConcept C143998085 @default.
• W3170396775 hasConcept C195910791 @default.
• W3170396775 hasConcept C2777511904 @default.
• W3170396775 hasConcept C2777982462 @default.
• W3170396775 hasConcept C2778527826 @default.
• W3170396775 hasConcept C2779413316 @default.
• W3170396775 hasConcept C2779786085 @default.
• W3170396775 hasConcept C2781164504 @default.
• W3170396775 hasConcept C2908647359 @default.
• W3170396775 hasConcept C530470458 @default.
• W3170396775 hasConcept C71924100 @default.
• W3170396775 hasConcept C99454951 @default.
• W3170396775 hasConceptScore W3170396775C121608353 @default.
• W3170396775 hasConceptScore W3170396775C126322002 @default.
• W3170396775 hasConceptScore W3170396775C143998085 @default.
• W3170396775 hasConceptScore W3170396775C195910791 @default.
• W3170396775 hasConceptScore W3170396775C2777511904 @default.
• W3170396775 hasConceptScore W3170396775C2777982462 @default.
• W3170396775 hasConceptScore W3170396775C2778527826 @default.
• W3170396775 hasConceptScore W3170396775C2779413316 @default.
• W3170396775 hasConceptScore W3170396775C2779786085 @default.
• W3170396775 hasConceptScore W3170396775C2781164504 @default.
• W3170396775 hasConceptScore W3170396775C2908647359 @default.
• W3170396775 hasConceptScore W3170396775C530470458 @default.
• W3170396775 hasConceptScore W3170396775C71924100 @default.
• W3170396775 hasConceptScore W3170396775C99454951 @default.
• W3170396775 hasIssue "15_suppl" @default.
• W3170396775 hasLocation W31703967751 @default.
• W3170396775 hasOpenAccess W3170396775 @default.
• W3170396775 hasPrimaryLocation W31703967751 @default.
• W3170396775 hasRelatedWork W2803564892 @default.
• W3170396775 hasRelatedWork W2991146761 @default.
• W3170396775 hasRelatedWork W3164150197 @default.
• W3170396775 hasRelatedWork W3165829877 @default.
• W3170396775 hasRelatedWork W4206299960 @default.
• W3170396775 hasRelatedWork W4286632023 @default.
• W3170396775 hasRelatedWork W4287506054 @default.
• W3170396775 hasRelatedWork W4361274839 @default.
• W3170396775 hasRelatedWork W4368282709 @default.
• W3170396775 hasRelatedWork W4206882145 @default.
• W3170396775 hasVolume "39" @default.
• W3170396775 isParatext "false" @default.
• W3170396775 isRetracted "false" @default.
• W3170396775 magId "3170396775" @default.
• W3170396775 workType "article" @default.